Will focus on new research collaborations and create 130 new jobs
Eli Lilly is to double its research presence in San Diego, California, US with the expansion of its Biotechnology Centre to help accelerate the discovery of new medicines within the company's core therapeutic areas, including immunology.
Scheduled to be completed next year, the expansion will feature an additional 175,000ft2 (around 16,260m2) of working space and is expected to generate up to 130 new jobs.
Thomas Bumol, Senior Vice President, biotechnology and immunology research at Lilly, said: 'San Diego has been an important location for Lilly laboratories for more than a decade. The city is a global hub for biomedical research and talent, where collaboration between academic institutions and biotechnology thrives.
'We want to build on our success in San Diego through expanded collaborations that ultimately allow us to bring better medicines to people faster than ever before.'
The space will allow for closer collaboration among Lilly experts in discovery chemistry and research technologies and biotechnology.
Lilly first moved into the San Diego area in 2004 by acquiring Applied Molecular Evolution, which now operates as a subsidiary. The Lilly Biotechnology Centre was established in 2009 and is located near the University of California, San Diego, among other biomedical research institutions.